Article Text

Maintenance of immune response throughout childhood following serogroup c meningococcal conjugate vaccination in early childhood
  1. A Khatami1,
  2. AJ Pollard1,
  3. A Peters1,
  4. H Robinson1,
  5. A Thompson1,
  6. H Findlow2,
  7. MD Snape1
  1. 1Oxford Vaccine Group, University of Oxford, Oxford, UK
  2. 2Health Protection Agency, Manchester, UK


Background Serogroup C meningococcal (MenC) conjugate vaccines were introduced into the UK routine infant immunisation schedule in 1999, along with a “catch-up” campaign for those aged 1–25 years. Previous cross-sectional studies demonstrated children immunised in early childhood have lower MenC bactericidal antibody 5 years after immunisation than children immunised in late childhood, however the kinetics of antibody decline through childhood have not been evaluated in a longitudinal study. We aimed to evaluate the kinetics of antibody decline through childhood in a longitudinal study of a single cohort following a dose of MenC conjugate vaccine in early childhood, and to calculate the proportion of 11 to 13 year-olds with protective levels of bactericidal antibody 10 years after immunisation.

Method Stored sera obtained at multiple time-points between 2001 and 2010 from children who had received a single dose of MenC vaccine at age 1 to 3.5 years, were analysed for MenC serum bactericidal antibody using rabbit complement (rSBA).

Results The MenC rSBA geometric mean titre (GMT) at age 3.5 to 5 years, approximately one year after immunisation, was 8.0 (95% confidence interval [CI] 6.5-9.9, n = 292). Over the subsequent 9 years, rSBA GMT declined to 3.3 (CI 2.5-4.4, n = 98) at age 11.5-13.5 years. The percentage of children with rSBA titres >1:8 (threshold for protection) also declined from 38% (CI 35%-41%) to 15% (CI 12%-19%).

Conclusion MenC rSBA titres wane rapidly following vaccination in early childhood, without evidence of natural boosting of antibody levels through cross-reactive antigens. In the UK, consideration should be given to a routine adolescent booster of MenC vaccine to protect this cohort of children who are entering the potentially high risk period of adolescence, and to prevent a resurgence in nasopharyngeal carriage and maintain herd immunity.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.